AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02990208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger \& Pauli, 2011)
Study NCT03061110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stromal Vascular Fraction
Description: Stromal Vascular Fraction will be produced from the subject's own adipose tissue by the Tissue Genesis Icellator device.
Study NCT03061110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care will include over-the-counter and prescription methods to treat xerostomia.
Study NCT01776788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro injection, exenatide injection
Description: First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
Study NCT01776788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin lispro injection
Description: Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
Study NCT02066467 — intervention group
Intervention type: DEVICE
Intervention: Left Ventricular lead implant: ACUITY X4® Lead Family
Description: Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
Study NCT02620579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
Study NCT02620579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
Study NCT04508192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Both interventions are simple strength exercises without technical equipment
Study NCT04508192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both interventions are simple strength exercises without technical equipment
Study NCT01482793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
Study NCT02620579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Anatomy Education
Description: Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
Study NCT02620579 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Shoulder Anatomy Education
Description: Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
Study NCT02620579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Processing Education
Description: Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
Study NCT02620579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Processing Education
Description: Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
Study NCT03689998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement
Description: immediate implant placement in freshly extraction socket
Study NCT03471442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthetic
Description: General anesthesia administered as per preference of intra-operative attending anesthesiologist
Study NCT03471442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: General anesthesia administered as per preference of intra-operative attending anesthesiologist
Study NCT03471442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids
Description: Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
Study NCT02542956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: receive Exparel by injection
Study NCT02542956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: receive Marcaine in a pain pump
Study NCT03471442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
Study NCT02542956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: receive Marcaine by injection
Study NCT01399658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-guided brachytherapy
Description: MRI-guided application of brachytherapy
Study NCT01399658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3'-Deoxy-3'-18f-Fluorothymidine
Description: Assessing tumor proliferation in Gynecologic cancer
Study NCT03885115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Involves 12-weeks of education related to healthy behaviors, nutrition, and exercise from certified fitness instructors.
Study NCT04236934 — intervention group
Intervention type: OTHER
Intervention: Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis
Description: Questionnaire is about symptoms measured by Edmonton Symptom Assessment Score (ESAS) and dyspnea also by modified Borg Scale (MBS)
Study NCT03104712 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose #1
Description: 50g available carbohydrate
Study NCT03104712 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose #2
Description: 50g available carbohydrate
Study NCT03104712 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose #3
Description: 50g available carbohydrate
Study NCT01099436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT01099436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT01099436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT01099436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Study NCT01099436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy
Study NCT01099436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT02849015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Study NCT02849015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Study NCT02849015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Natural killer cell(each treatment: about 10 billion cells transfusion in 3 times, i.v.)
Study NCT03376685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Exercise Training (END)
Description: Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 5 days a week for 30 minutes (Week 1-2); 35 minutes (Weeks 3-4); or 40 minutes (Weeks 5-6) at 60% VO2 peak.
Study NCT03376685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint Exercise Training (SIT)
Description: Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 3 days a week involving a 3-minute warm-up, followed up 4 repetitions (Week 1-2); 5 repetitions (Weeks 3-4); or 6 (Weeks 5-6) repetitions of 30 seconds at a maximal intensity with 2 minutes' rest in between. Exercise will conclude with a 2-minute cool-down.
Study NCT03459365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euflexxa
Description: Aspirations performed before each injection and at six weeks.
Study NCT03689998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate implant placement
Description: immediate implant placement in freshly extraction socket
Study NCT03689998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: topical application of melatonin
Study NCT02206425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study NCT02206425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study NCT02206425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study NCT05179291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buzzy Group
Description: The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.
Study NCT05179291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Realitiy-VR Group
Description: VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
Study NCT03216564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Active vitamin D (Calcitriol) 0.25 micrograms
Study NCT03104712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spaghetti
Description: 50g available carbohydrate
Study NCT03104712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice
Description: 50g available carbohydrate
Study NCT02206425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study NCT02206425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study NCT02206425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study NCT02206425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study NCT02206425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study NCT01290666 — intervention group
Intervention type: DEVICE
Intervention: Fistula Plug
Description: Bioabsorbable fistula plug
Study NCT04094922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swedish PTSD Coach smartphone app
Description: Self-help smartphone app targeted towards posttraumatic stress that includes psychoeducation, rating/monitoring of distress, lists of support and treatment resources, and strategies for coping with distress.
Study NCT04283006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD20/CD22 dual Targeted CAR T-cells
Description: Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
Study NCT04634864 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: 40 minutes of 2mA intensity direct current stimulation was delivered over both the right and left motor cortex simultaneously
Study NCT04634864 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The stimulator was switched off after 2 minutes of stimulation.
Study NCT03330431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Description: All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
Study NCT03330431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Description: All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
Study NCT02763852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.
Study NCT02763852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
Study NCT02763852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 125
Description: Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
Study NCT04976361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
Description: PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
Study NCT04220372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxinluo
Description: Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
Study NCT04220372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
Study NCT05368740 — intervention group
Intervention type: DEVICE
Intervention: integrated pulmonary index monitor
Description: Integrated Pulmonary Index (IPI) is a new monitoring method calculated using respiratory rate (RR), end-tidal carbon dioxide (EtCO2), peripheral oxygen saturation (SpO2), and heart rate (HR). It is designed to obtain information about the patients' oxygenation and ventilation in the form of a single value or waveform from 1 to 10 with a mathematical algorithm using fuzzy logic. According to this scoring system; 10= normal, 8-9= within normal range, 7= close to normal range, requires attention, 5-6= requires attention and may require intervention, 3-4= requires intervention, 1-2= requires immediate intervention \[2\].
Study NCT03471442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics, Local
Description: Weight-based dosing of this local anesthetic mixture.